Exploring current shortfalls and potential improvements for non-viral gene delivery in cystic fibrosis

Within the last decade, the treatment options for patients with cystic fibrosis (CF) have greatly improved with the rise of genotype-specific therapies. However, there remain patients for whom these therapies do not work. David McCall, Senior Editor at BioInsights, speaks with Uta Griesenbach, Professor, Imperial College London, about her research with both viral and non-viral gene therapy approaches aimed at these treatment-resistant patients, and discusses next steps in the space for non-viral delivery in particular.

Please enter your email to access content Read now